glaucoma

Bimatoprost sustained-release implants: Potential new pathway for glaucoma patientsThe bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.
Ceeable aims to be the next gold standard in visual fields
Ceeable aims to be the next gold standard in visual fieldsCeeable, a web-based, mobile digital technology designed to detect early-stage eye diseases—an innovation that can help shape 21st century medicine—was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.
Optometrists should get involved in national politics, says OD RNC speaker
Optometrists should get involved in national politics, says OD RNC speakerAfter speaking at last week’s Republican National Convention in Cleveland, New Mexico OD Lisa Shin says more optometrists should get involved on a national level to keep optometry’s agenda at the forefront.
Check out a recap from the 2016 Glaucoma 360 gala!
Check out a recap from the 2016 Glaucoma 360 gala!From the silent auction, art sales, and an opera performance, the 2016 Glaucoma 360 gala was one not to be soon forgotten.
Santen to acquire InnFocus, developer of glaucoma drainage implantSanten Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.
Portable non-mydriatic device closes gap on tele-glaucoma screeningA portable non-mydriatic fundus camera was found useful in grading cup-to-disc ratio as part of glaucoma screening compared with a standard tabletop mydriatic fundus camera.
Glaucoma risk may increase after cataract removal in early infancy
Glaucoma risk may increase after cataract removal in early infancyGlaucoma is more likely to develop in children who undergo cataract surgery when they are 6 weeks or younger.
Three companies on the “Horizon” with glaucoma drugsThe pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
B + L dedicated to eye care with strong portfolio, new programsBausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.
FDA making changes in approval processes for industry, patientsThe laws governing ophthalmic drug and device approvals have changed little in recent years. But the FDA is making significant and far-reaching changes in its approvals process.